GE HealthCare agreed to acquire SOFIE Biosciences, a U.S. contract manufacturer of PET radiopharmaceuticals, from Trilantic North America for $945 million in cash. SOFIE operates 15 CMO sites and already manufactures GE HealthCare's Flyrcado F18 product; it will join the PDx pharmaceutical diagnostics segment on closing, expected in the first half of 2027. GE HealthCare also gains U.S. rights to pipeline tracer FAPI-74.
Aurora Cannabis said Curaleaf has yet to formally file its revised hostile offer of US$5.00 per share in stock and cash, and repeated its recommendation that shareholders take no action.
iRhythm closed its purchase of wearable biosensor and ambulatory cardiac monitoring company VitalConnect, adding mobile cardiac telemetry and multi-vitals capability.
CRO Lanterne Dx completed its merger with Ampersand-backed digital pathology firm Flagship Biosciences; the combined company keeps the Lanterne Dx name under CEO Jon Bishop.
Resonant bought Hamburg-based labfish rental solutions and its U.S. and UK affiliates, expanding its clinical equipment and ancillaries footprint in Europe.
CD&R and McKesson signed a definitive agreement to acquire Option Care Health, an independent provider of home and alternate site infusion services, for $32.05 per share in cash, reflecting a total enterprise value of about $5.8 billion. The Nasdaq-listed company will be taken private through the joint private equity and strategic partnership.
NextPlat Corp closed the purchase of an independent pharmacy near Pensacola for $1,485,439 in cash; the profitable business generated about $5.6 million in 2025 sales.
Repligen Corporation has closed its previously announced acquisition of Nasdaq-listed BioLife Solutions, a developer of cell processing tools and biopreservation media for the cell and gene therapy market. BioLife's CryoStor-led portfolio supports 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based trials, adding what Repligen calls a high-margin consumables business with recurring revenue to its bioprocessing lineup.
Simulations Plus, the Nasdaq-listed developer of model-informed and AI-accelerated drug development software, announced the completion of its acquisition by affiliates of healthcare-focused investment firm Altaris. The transaction was originally announced on June 16, 2026, and shares of the company were converted at the effective time of the merger.
Harrow has completed its acquisition of TYRVAYA nasal spray, the first and only FDA-approved nasal spray for dry eye disease, from Viatris. Harrow paid $30 million in cash at closing from cash on hand and may pay up to $70 million in milestones tied to net sales, for potential total consideration of $100 million. Harrow acquired worldwide rights except Japan, where Viatris retains commercialization and will pay royalties.
Evident closed its purchase of CrestOptics S.p.A., a Rome-based maker of spinning disk confocal and super-resolution microscopy systems, broadening its life science imaging portfolio.
European life sciences investor Samfara completed its first investment, acquiring controlled-substance API manufacturer Chr. Olesen Synthesis from Chr. Olesen and funds managed by Signet Healthcare Partners on undisclosed terms.
Resonant acquired Hamburg-based labfish rental solutions GmbH and its US and UK subsidiaries, adding clinical and lab equipment rental, calibration and IOR/EOR capabilities across more than 70 countries.
Standard Dental Labs acquired substantially all operating assets of Dr. Tooth, LLC, adding an estimated $800,000 in annualized revenue and lifting SDL's estimated annualized revenue base above $1.6 million.
Wandercraft acquired Ekso Bionics from a subsidiary of ChronoScale Holdings, combining the two medical exoskeleton pioneers across EMEA and U.S. markets.
Axogen completed its acquisition of BioCircuit Technologies, maker of the first FDA-cleared sutureless nerve repair device, expected to add about $34 million to 2027 revenue.
European life sciences investor Samfara completed its first investment, acquiring controlled-substance API manufacturer Chr. Olesen Synthesis from Chr. Olesen and Signet Healthcare Partners funds; terms undisclosed.
Banner Capital formed Seaway Group and agreed to acquire Seaway Plastics Engineering, MME Group and Wright Engineered Plastics, with Seventeen Capital co-investing and Ron Labrum as executive chairman.